Pfizer Inc. (NYSE:PFE) acquired Metsera for $10 billion, a company working on a monthly GLP-1 shot. The shot aims to compete in the weight loss market. Pfizer CEO, Dr. Albert Bourla, highlighted the potential of this acquisition on a recent episode of Squawk on the Street. The deal includes upfront and milestone payments totaling $85.25 per share. Pfizer aims to tap into the growing GLP-1 market with this strategic move.

Read more at Yahoo Finance: Jim Cramer Says “I Think Pfizer’s Very Smart to Buy Metsera”